Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CorMedix Revised Guidance Of Pro Forma 2025 Combined Revenues To $325M-$350M Vs. Consensus Of $215.14M, Melinta Therapeutics Deal Expected to be near-term accretive to EPS with double-digit accretion expected in 2026

Author: Benzinga Newsdesk | September 02, 2025 06:39am

Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million

Revised Full Year Financial Guidance

  • Pro forma 2025 Revenue: $325 million – $350 million
  • Pro forma 2025 Synergized Adjusted EBITDA: $165 million – $185 million
  • DefenCath® 2025 Revenue: $200 million – $215 million

Posted In: CRMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist